Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Amsterdam, Netherlands Clinical Trials

A listing of Amsterdam, Netherlands clinical trials actively recruiting patients volunteers.

RESULTS

Found (41) clinical trials

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. PROCLAIM: PRObody CLinical Assessment In Man CX-2009 clinical trial 001 PROBODY is a trademark of CytomX ...

Phase

0.0 miles

Learn More »

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas. PROCLAIM-CX-072: PRObody ...

Phase

0.0 miles

Learn More »

APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma

The study will consist of 2 phases, a Phase I/dose escalation phase and a Phase II/expansion phase. Patients with relapsed and relapsed or refractory multiple myeloma will be enrolled in both phases of the study. Eligible patients will undergo leukapheresis in order to harvest T cells, which is the starting ...

Phase

0.0 miles

Learn More »

Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium

The purpose of this study is to assess the efficacy and performance of the C2 Focal Cryoablation System in patients with BE. The study will involve up to 50 subjects with each subject receiving cryoablation therapy of all visible BE using the C2 System Focal Ablation System. Length of ablation ...

Phase

0.0 miles

Learn More »

Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma

This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6). The primary objectives of this study are: Phase 1 Study: ...

Phase

0.0 miles

Learn More »

TIBOHCA: Safety Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After OHCA

Objective The primary objective of this study is to evaluate the short term safety and tolerability, and the pharmacokinetic properties of 2-IB when administered to adult patients after OHCA. Study design: A Phase 2, single-centre, open-label, dose-escalation intervention study. Study population: The study population will constitute of three cohorts of ...

Phase

0.0 miles

Learn More »

An Open-Label Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

This is an open-label, dose-escalation/dose-expansion study of INCB059872 in subjects with advanced malignancies. The study will be conducted in 4 parts. Part 1 (mono therapy dose escalation) will determine the recommended dose(s) of INCB059872 for dose expansion, based on maximum tolerated dose and/or a tolerated pharmacologically active dose. Part 2 ...

Phase

0.0 miles

Learn More »

A Study of MCLA-128 in Patients With Solid Tumors Harboring an NRG1 Fusion

Study Design : This open label (all participants know the identity of the study drug), multicenter (more than one study site), first-in-human study consisting of 2 parts. Part 1 is a dose escalation and Part 2 is a dose expansion cohort. Part 1 has been completed. Part 2 new patient ...

Phase

0.24 miles

Learn More »

131I-IPA + XRT as Treatment for Patients With Glioblastoma Multiforme

Primary objective To assess the safety and tolerability of intravenous 131I-IPA administered concomitantly to 2nd line XRT in recurrent GBM Secondary objectives To assess the maximum tolerated dose (MTD) of 131I -IPA administered concomitantly to 2nd line XRT in recurrent GBM To evaluate the feasibility of a fractionated administration of ...

Phase

0.24 miles

Learn More »

Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer

Rationale: Currently, third line systemic treatment for patients with advanced, wild type K-RAS and as has recently been demonstrated with wild type N-RAS (thereafter referred to as wild type RAS) colorectal cancer (CRC) includes epidermal growth factor receptor (EGFR) inhibition with the anti-EGFR antibody cetuximab. This type of treatment has ...

Phase

0.28 miles

Learn More »